Constipation News and Research RSS Feed - Constipation News and Research

Constipation is a condition in which stool becomes hard, dry, and difficult to pass, and bowel movements don’t happen very often. Other symptoms may include painful bowel movements, and feeling bloated, uncomfortable, and sluggish.
Auriculotherapy may help in managing chronic constipation

Auriculotherapy may help in managing chronic constipation

Nearly 1 in 6 adults worldwide may suffer from chronic constipation and, over time, the disorder can cause serious complications. Auriculotherapy, a form of acupuncture that involves stimulating targeted points on the outer ear, may help in managing constipation. [More]
Experts available to share tips on prevention of ovarian cancer

Experts available to share tips on prevention of ovarian cancer

Ovarian cancer is the fourth leading cause of death in American women, with about 22,000 diagnosed and 14,000 dying from the disease each year. September is Ovarian Cancer Awareness month and Mount Sinai experts are sharing tips on prevention. [More]
Young girls with vulvitis may be at increased risk of developing urinary tract infections

Young girls with vulvitis may be at increased risk of developing urinary tract infections

Young girls with an intense, red, itchy rash on their outer genital organs may be at increased risk of developing urinary tract infections (UTIs), according to new research from Wake Forest Baptist Medical Center. The treatment may be as simple as better hygiene and avoiding potential irritants such as bubble baths and swimming pools. [More]
Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS). [More]
Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C. [More]
Anti-cholinergic drugs could be responsible for decline in cognitive, physical function in elderly patients

Anti-cholinergic drugs could be responsible for decline in cognitive, physical function in elderly patients

Drugs widely prescribed to the elderly could be responsible for a decline in cognitive and physical function according to research from the University of East Anglia and the Regenstrief Institute. [More]
EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union. [More]
EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union. [More]
Study examines mechanism of bone-protective properties of California dried plums

Study examines mechanism of bone-protective properties of California dried plums

Fifty-seven million Americans suffer from low bone density or osteoporosis, a disease which causes bones to become so weak and brittle that even a minor fall or other stresses may cause fractures. [More]
Researcher finds genetic identifier that may allow clinicians to determine babies at risk for autism

Researcher finds genetic identifier that may allow clinicians to determine babies at risk for autism

A researcher at Seattle Children's Hospital and Research Institute has found a genetic identifier for autism that includes physical features that may eventually allow clinicians to identify babies who are at risk for autism before they are born. [More]
Once-a-day pill for patients experiencing opioid-induced constipation

Once-a-day pill for patients experiencing opioid-induced constipation

Opioids - strong morphine-based painkillers - are widely prescribed to patients experiencing chronic severe pain. While these drugs are very effective for treating and managing pain, they have one particularly bothersome side effect: constipation. [More]
Urge incontinence therapy may relieve stress incontinence

Urge incontinence therapy may relieve stress incontinence

Anticholinergic medication appears to be effective as a treatment for stress and mixed urinary incontinence, results of a small clinical trial indicate. [More]
Sleep problems in PD patients can worsen in later stages of disease

Sleep problems in PD patients can worsen in later stages of disease

Up to 70% of Parkinson's disease (PD) patients experience sleep problems that negatively impact their quality of life. [More]
Combining NRT with varenicline improves smoking abstinence

Combining NRT with varenicline improves smoking abstinence

Combining the smoking cessation medication varenicline with nicotine replacement therapy was more effective than varenicline alone at achieving tobacco abstinence at 6 months, according to a study in the July 9 issue of JAMA. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
Forecast report on Global Ovarian Cancer market

Forecast report on Global Ovarian Cancer market

Research and Markets has announced the addition of the "Global Ovarian Cancer Market 2014-2018" report to their offering. [More]
Thyroxine may overcome mutated thyroid hormone receptor effects

Thyroxine may overcome mutated thyroid hormone receptor effects

Patients with a mutation in the thyroid hormone receptor α gene that affects both the thyroid hormone receptor α1 and α2 protein variants have similar characteristics to patients with mutations affecting only the α1 variant, report researchers. [More]
Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. [More]
Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile) [More]
Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain. [More]